The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | LIMBER-TREG108: CK0804 add-on therapy in patients with MF with suboptimal response to ruxolitinib
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the rationale for the ongoing LIMBER-TREG108 trial (NCT05423691). The study aims to evaluate the safety and tolerability of CK0804, a novel allogeneic regulatory T cell (Treg) therapy, as an add-on treatment for patients with myelofibrosis (MF) who have not responded optimally to ruxolitinib. CK0804 is CXCR4 enriched, which is designed to selectively target the bone marrow and resolve inflammation to restore normal hematopoietic function.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
